Several studies demonstrated that apatinib plus EGFR-TKIs (gefitinib) exhibited a tolerable safety profile and encouraging antitumor activity for advanced EGFR-mutant NSCLC [52–54]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.